ReviewMolecular oncology2013
What are the best routes to effectively model human colorectal cancer?
Review in Molecular oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Predicting colorectal cancer risk in FAP patients using patient-specific organoids.Cancer gene therapy · 2025Article
- Role of Gut Microbiota in Predisposition to Colon Cancer: A Narrative Review.Indian journal of microbiology · 2024Review
- Human Hepatobiliary Organoids: Recent Advances in Drug Toxicity Verification and Drug Screening.Biomolecules · 2024Review
- MKRN1 promotes colorectal cancer metastasis by activating the TGF-β signalling pathway through SNIP1 protein degradation.Journal of experimental & clinical cancer research : CR · 2023Article
- Familial adenomatous polyposis and changes in the gut microbiota: New insights into colorectal cancer carcinogenesis.World journal of gastrointestinal oncology · 2021Review
- Heterozygous APC germline mutations impart predisposition to colorectal cancer.Scientific reports · 2021Article
- Modeling colorectal cancers using multidimensional organoids.Advances in cancer research · 2021Review
- Molecular Targets in Precision Chemoprevention of Colorectal Cancer: An Update from Pre-Clinical to Clinical Trials.International journal of molecular sciences · 2020Review
- Establishment of an Endoscopy-Guided Minimally Invasive Orthotopic Mouse Model of Colorectal Cancer.Cancers · 2020Article
- Review
- The role of mouse models in colorectal cancer research-The need and the importance of the orthotopic models.Animal models and experimental medicine · 2020Review
- Cross-talk between Hippo and Wnt signalling pathways in intestinal crypts: Insights from an agent-based model.Computational and structural biotechnology journal · 2020Article
- Biodegradable fluorescent nanoparticles for endoscopic detection of colorectal carcinogenesis.Advanced functional materials · 2019Article
- A multi-site metastasis-on-a-chip microphysiological system for assessing metastatic preference of cancer cells.Biotechnology and bioengineering · 2019Article
- The chemopreventive effect of withaferin A on spontaneous and inflammation-associated colon carcinogenesis models.Carcinogenesis · 2018Article
- A genetically inducible porcine model of intestinal cancer.Molecular oncology · 2017Article
- Mesenchymal stem cells support growth and organization of host-liver colorectal-tumor organoids and possibly resistance to chemotherapy.Biofabrication · 2017Article
- Dietary fat overcomes the protective activity of thrombospondin-1 signaling in the Apc(Min/+) model of colon cancer.Oncogenesis · 2016Article
- Mouse model of proximal colon-specific tumorigenesis driven by microsatellite instability-induced Cre-mediated inactivation of Apc and activation of Kras.Journal of gastroenterology · 2016Article
- The TGF-β pathway is activated by 5-fluorouracil treatment in drug resistant colorectal carcinoma cells.Oncotarget · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Colorectal cancer (CRC) is the third most common cancer in the UK, with over 37,500 people being diagnosed every year. Survival rates for CRC have doubled in the last 30 years and it is now curable if diagnosed early, but still over half of all sufferers do not survive for longer than 5 years after diagnosis. The major complication to treating this disease is that of metastasis, specifically to the liver, which is associated with a 5 year survival of less than 5%. These statistics highlight the importance of the development of earlier detection techniques and more targeted therapeutics. The future of treating this disease therefore lies in increasing understanding of the mutations which cause tumourigenesis, and insight into the development and progression of this complex disease. This can only be achieved through the use of functional models which recapitulate all aspects of the human disease. There is a wide range of models of CRC available to researchers, but all have their own strengths and weaknesses. Here we review how CRC can be modelled and discuss the future of modelling this complex disease, with a particular focus on how genetically engineered mouse models have revolutionised this area of research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.